Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

AKTX vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: AKTX 0 – 5 EQ (1 Tie) Matrix Metrics: AKTX 3 – 5 EQ

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKTX vs EQ
AKTX NASDAQ
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$6.71
+0.9% 1D
Market Cap $16.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 81.68β · 145% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.9%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $7.57 · SMA50: $8.56
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (AKTX 0 – 5 EQ)

Columns: Metric · AKTX · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue N/M 7.7x
2. Growth & Scale EQ
Revenue Growth (YoY) +0.0% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.4M
Market Cap $16.3M $90.6M
3. Profitability & Quality EQ
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.3% -59.0%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) N/A -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.66 Book/Sh · -146.3% ROE $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 261.3% (100th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKTX (3) vs EQ (5)
Institutional Metric AKTX EQ Criterion Row Edge
Market Capitalization
Scale
$16.3M $90.6M Larger Scale EQ
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
+0.0% -52.3% Higher Growth AKTX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.3% -59.0% Higher ROE EQ
52-Week Range Position
Momentum
23% ($0–$29) 11% ($1–$4) Stronger Trend AKTX
Beta / 30D Volatility
Risk Regime
81.68β · 145% Vol 1.53β · 93% Vol Lower Realized Risk EQ
Unified Institutional Score
Composite Signal
53.0 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite AKTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($7.66 Book/Sh · -146.3% ROE) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EQ +2.27 pp
AKTX: -23.4% · EQ: -21.13%
3M Horizon AKTX +37.0 pp
AKTX: -14.52% · EQ: -51.52%
6M Horizon AKTX +79.86 pp
AKTX: +30.54% · EQ: -49.32%
1Y Horizon AKTX +1151.65 pp
AKTX: +1163.65% · EQ: +12.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTX vs EQ. Trailing 12-month operating profitability (AKTX 0.0% vs EQ 0.0%) and valuation multiples (AKTX N/M vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.

AKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-146.3% · N/M
EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKTX vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY). Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EQ leads the Growth & Scale pillar: AKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, AKTX generates N/A in USD-normalized revenue versus $4.4M for EQ. In operating R&D and SG&A reinvestment, AKTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTX (-146.3% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (81.68β · 145% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.